APDN insider filings
APPLIED DNA SCIENCES INC — 27 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-03-27. Screen APDN transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for APDN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — APPLIED DNA SCIENCES INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-03-27 | 4 | Shorrock Clay — Chief Legal Officer | Grant/award (A): 91,667 @ $0 · Grant/award (A): 98,039 (derivative) @ $0 · Grant/award (A): 1,961 (derivative) @ $0 | EDGAR |
| 2023-03-27 | 4 | Jantzen Beth — Chief Financial Officer | Grant/award (A): 91,667 @ $0 · Grant/award (A): 98,039 (derivative) @ $0 · Grant/award (A): 1,961 (derivative) @ $0 | EDGAR |
| 2023-03-27 | 4 | Murrah Judith — CIO and COO | Grant/award (A): 99,306 @ $0 · Grant/award (A): 98,039 (derivative) @ $0 · Grant/award (A): 10,294 (derivative) @ $0 | EDGAR |
| 2023-01-27 | 4 | Schmalz Elizabeth M — Director | Grant/award (A): 75,099 (derivative) @ $0 · Grant/award (A): 40,366 (derivative) @ $0 | EDGAR |
| 2023-01-27 | 4 | Anchin Scott L — Director | Grant/award (A): 75,099 (derivative) @ $0 · Grant/award (A): 37,550 (derivative) @ $0 | EDGAR |
| 2023-01-27 | 4 | Ceccoli Joseph D. — Director | Grant/award (A): 75,099 (derivative) @ $0 · Grant/award (A): 41,305 (derivative) @ $0 | EDGAR |
| 2023-01-27 | 4 | Simon Sanford R — Director | Grant/award (A): 75,099 (derivative) @ $0 · Grant/award (A): 38,489 (derivative) @ $0 | EDGAR |
| 2023-01-27 | 4 | CATELL ROBERT B — Director | Grant/award (A): 75,099 (derivative) @ $0 · Grant/award (A): 39,428 (derivative) @ $0 | EDGAR |
| 2023-01-27 | 4 | SHAMASH YACOV A — Director | Grant/award (A): 75,099 (derivative) @ $0 · Grant/award (A): 46,938 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | Shorrock Clay — Chief Legal Officer | Grant/award (A): 19,924 (derivative) @ $0 · Grant/award (A): 25,205 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | Ferguson Elizabeth M. — Director | Grant/award (A): 19,897 (derivative) @ $0 · Grant/award (A): 9,948 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | Anchin Scott L — Director | Grant/award (A): 19,897 (derivative) @ $0 · Grant/award (A): 9,948 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | Jantzen Beth — Chief Financial Officer | Grant/award (A): 19,924 (derivative) @ $0 · Grant/award (A): 25,205 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | Ceccoli Joseph D. — Director | Grant/award (A): 19,897 (derivative) @ $0 · Grant/award (A): 10,943 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | Bitzer John III — Director | Grant/award (A): 19,897 (derivative) @ $0 · Grant/award (A): 11,689 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | Murrah Judith — CIO and COO | Grant/award (A): 19,924 (derivative) @ $0 · Grant/award (A): 32,203 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | Simon Sanford R — Director | Grant/award (A): 19,897 (derivative) @ $0 · Grant/award (A): 10,197 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | Hayward James A — Chairman, CEO and President, Director | Grant/award (A): 19,924 (derivative) @ $0 · Grant/award (A): 199,243 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | CATELL ROBERT B — Director | Grant/award (A): 19,897 (derivative) @ $0 · Grant/award (A): 9,948 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | SHAMASH YACOV A — Director | Grant/award (A): 19,897 (derivative) @ $0 · Grant/award (A): 11,937 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4 | Anchin Scott L — Director | Sale (S): 11,999 @ $8.43 · Sale (S): 210 @ $8.47 · Sale (S): 610 @ $8.45 · Sale (S): 201 @ $8.51 · Sale (S): 29 @ $8.52 | EDGAR |
| 2021-03-08 | 4 | Anchin Scott L — Director | Option exercise (M): 9,217 @ $4.26 · Option exercise (M): 3,832 @ $4.43 · Option exercise (M): 20,834 (derivative) @ $0 · Option exercise (M): 9,121 (derivative) @ $0 | EDGAR |
| 2021-01-07 | 4 | Hayward James A — Chairman, CEO and President, Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2020-10-21 | 4 | Anchin Scott L — Director | Grant/award (A): 5,573 (derivative) @ $0 · Grant/award (A): 18,465 (derivative) @ $0 | EDGAR |
| 2020-10-21 | 4 | Jantzen Beth — Chief Financial Officer | Grant/award (A): 13,035 (derivative) @ $0 | EDGAR |
| 2020-10-21 | 4 | Murrah Judith — Chief Information Officer | Grant/award (A): 13,035 (derivative) @ $0 | EDGAR |
| 2020-10-21 | 4 | Hayward James A — Chairman, CEO and President, Director | Grant/award (A): 13,035 (derivative) @ $0 | EDGAR |
Recent 8-K events — APPLIED DNA SCIENCES INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-02 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-13 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-25 | 8-K/A | 3.02 — Unregistered Sales of Equity Securities | EDGAR |
| 2026-06-03 | 8-K/A | 3.02 — Unregistered Sales of Equity Securities | EDGAR |
Registration filings — APPLIED DNA SCIENCES INC
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-298025 (S-1) — latest: Initial registration (S-1), filed 2026-08-05
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=APDN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs